Researchers have also shown that CIN can predict which patients are most likely to benefit from specific treatments, such as bevacizumab (an anti-angiogenic monoclonal antibody targeting vascular endothelial growth factor A [VEGF-A]), a key drug used in the treatment of colorectal and lung cancers [125]. Here, VEGFA is linked to lung cancer.